drugset / Trial / NCT03749135
Dupilumab in Chronic Spontaneous Urticaria
Phase 2
Completed
72 enrolled
Charite University, Berlin, Germany
Proinnovera GmbH · collabSanofi · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with chronic spontaneous urticaria (CSU) who are symptomatic despite H1-antihistamine treatment.
Timeline
- Start
- 2018-11-12
- Primary completion
- 2021-07-07
- Completion
- 2021-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | — | Subcutaneous |